CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002894: Neoplasm of the pancreasHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug848 Endoscopic management according to standard of care Wiki 0.58
drug1756 Palliative care assessment Wiki 0.58
drug754 Dexmethylphenidate Wiki 0.58
drug874 Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer Wiki 0.58

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D010190 Pancreatic Neoplasms NIH 1.00
D007565 Jaundice, NIH 0.58
D002761 Cholangitis NIH 0.58
D018281 Cholangiocarcinoma NIH 0.58
D008105 Liver Cirrhosis, Biliary NIH 0.58
D041781 Jaundice, Obstructive NIH 0.58

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0030153 Cholangiocarcinoma HPO 0.58
HP:0002613 Biliary cirrhosis HPO 0.58
HP:0000952 Jaundice HPO 0.58
HP:0030151 Cholangitis HPO 0.58

There are 3 clinical trials

Clinical Trials


1 The Impact of Early Palliative Care on the Quality of Life of Patients With Advanced Pancreas Cancer: A Case-crossover Study

The primary objective is to explore the impact of early palliative care on quality of life in patients with advanced pancreatic cancer. The secondary objectives are to explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer.

NCT03837132 Advanced Cancer Behavioral: Palliative care assessment
MeSH:Pancreatic Neoplasms
HPO:Neoplasm of the pancreas

Primary Outcomes

Description: For the primary endpoint, we will use a generalized linear model to test for a statistically significant change score between baseline and 16 weeks. We will assume a normal distribution for the change scores. Model fit will be assessed via a visual assessment of residuals and the ratio of the model deviance to its degrees of freedom.

Measure: Impact of early palliative care on quality of life in patients with advanced pancreatic cancer

Time: registration to 16 weeks

Secondary Outcomes

Description: Secondary endpoints will include: (1) symptom control at 16 weeks as measured by the revised Edmonton Symptom Assessment Scale (ESAS-r) (a widely used and validated tool to assess symptom intensity, which is routinely completed by patients at all CCMB visits); (2) depression and anxiety at 16 weeks using the Hospital Anxiety and Depression Scale (HADS) (a 14 item scale which can be used in the outpatient setting to screen for anxiety and depression within the previous week) and the Patient Health Questionnaire (PHQ-9) (a sensitive (88%) and specific (88%) 9 question tool which incorporates diagnostic criteria for major depression); and overall survival measured from date of registration to death

Measure: To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer

Time: registration to 16 weeks

2 Effects of Covid-19 Pandemic on Pancreatic Surgery in Italy. A Multicenter Observational Clinical Study

Pancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.

NCT04380766 Pancreatic Cancer Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
MeSH:Pancreatic Neoplasms
HPO:Neoplasm of the pancreas

Primary Outcomes

Measure: Changes in pancreatic cancer management during the COVID-19 pandemic

Time: From admission to discharge/last outpatient visit, whichever comes first, assessed up to the 30th of June 2020

3 The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study

In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.

NCT04385147 Cholangitis, Secondary Biliary Cholangiocarcinoma Obstructive Jaundice Pancreas Cancer COVID-19 SARS-CoV-2 Other: Endoscopic management according to standard of care
MeSH:Cholangiocarcinoma Pancreatic Neoplasms Cholangitis Liver Cirrhosis, Biliary Jaundice Jaundice, Obstructive
HPO:Biliary cirrhosis Cholangiocarcinoma Cholangitis Jaundice Neoplasm of the pancreas

Primary Outcomes

Description: Investigators will report the baseline demographic data (age, gender, nationality) of all patients.

Measure: Age, gender, nationality

Time: 3 months

Description: Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.

Measure: Indication for procedure, status of SARS-CoV-2 infection

Time: 3 months

Description: Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.

Measure: Complete blood count and liver functions tests

Time: 3 months

Description: Investigators will report the procedure related complications.

Measure: procedure related complications

Time: 3 months

Secondary Outcomes

Description: Investigators will report wether the precautions lead to increase timing of the procedure

Measure: Effect of COVID-19 precautions on procedure time

Time: 3 months

Description: Investigators will report wether the precautions affected staff number (increased or decreased)

Measure: Effect of COVID-19 precautions on staff number

Time: 3 months


HPO Nodes